8-K filing — Theriva Biologics, Inc. (TOVX)
Filed: 2026-08-11 AccNo: 0001104659-26-093782 Size: 310 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Theriva Biologics Announces Publication Of Clinical, Translational Results From VCN-01's Phase 1 Clinical Trial In Head & Neck Squamous Cell Carcinoma In Clinical Cancer Research Journal
– Prolonged overall survival (OS) was observed in heavily pre-treated refractory Head & Neck Squamous Cell Carcinoma (HNSCC) patients administered IV VCN-01 prior to the immune checkpoint inhibitor durvalumab ––
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Theriva Biologics Q2 EPS $(0.07) Misses $(0.05) Estimate
Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 96.37 percent increase over losses of $(1.93) per share from
Theriva Biologics Doses First Patient In VIRAGE2 Phase 2a Clinical Trial, Small Proof-Of-Concept Study Evaluating More Frequent Repeated Dosing Of VCN-01 In First-Line Metastatic PDAC Patients Treated With Gemcitabine/Nab-Paclitaxel Chemotherapy
Theriva Biologics Receives Spanish Agency Of Medicines And Medical Devices Authorization To Initiate Its VIRAGE2 Clinical Trial